Kiora Pharmaceuticals Inc
KPRX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001372514
No open-market purchases or sales by Kiora Pharmaceuticals Inc insiders were filed in the last 90 days; 22 institutions reported holding it in 13F filings for Q2 2026, worth $2.91M in total; no superinvestor holds it.
Other share classesKPHMW
Q3 2022 vs. Q2 2022
How the institutions holding Kiora Pharmaceuticals Inc changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 14 | 9 | −5 |
| Shares | 836.2K | 34.1K | −802.1K (−95.9%) |
| Value | $391.0K | $209.0K | −$182.0K (−46.5%) |
New holders (1)
Institutions that held Kiora Pharmaceuticals Inc at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Spartan Fund Management Inc. | 1,000 | $6.00K | 0.00% |
Sold out (6)
Institutions that held Kiora Pharmaceuticals Inc at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Vanguard Group Inc | 67,212 | $31.0K |
| Price T Rowe Associates Inc | 51,300 | $24.0K |
| Citadel Advisors LLC | 46,440 | $22.0K |
| Renaissance Technologies LLC | 41,835 | $20.0K |
| Captrust Financial Advisors | 15,000 | $7.00K |
| Tower Research Capital LLC (TRC) | 12,558 | $6.00K |